Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud affecting investors between August 3, 2023, and December 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made misleading statements regarding the efficacy of setrusumab, particularly that while it increases bone density, it does not correlate with a decrease in annualized fracture rates [1] - On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing annualized clinical fracture rates compared to placebo or bisphosphonates [1] - Following the announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in just one day [1] Group 2: Investor Information - Investors who suffered losses during the relevant time frame have until April 6, 2026, to request to be appointed as lead plaintiff in the lawsuit [1] - Class members may be entitled to compensation without any out-of-pocket costs or fees [1] - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged material misstatements regarding its drug setrusumab, with a deadline for investors to seek lead plaintiff status set for April 6, 2026 [1] Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [1] - The complaint alleges that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients and downplayed risks associated with its Phase III Orbit study [1] - Defendants are accused of making misleading statements about the company's business and prospects, lacking a reasonable basis for their optimism [1] Group 2: Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to consider filing for lead plaintiff status by the April 6, 2026 deadline [1] - Options for investors include retaining counsel or taking no action, with the ability to remain an absent class member [1] - The lead plaintiff will represent all class members and is typically the investor with the largest financial interest [1]

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased its common stock during the specified class period, alleging misleading statements regarding clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Ultragenyx shares from August 3, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations - The complaint claims that Ultragenyx misled investors by raising expectations about the ORBIT and COSMIC studies, which tested setrusumab for Osteogenesis Imperfecta, while concealing that neither study significantly reduced clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Ultragenyx's share price fell from $34.19 on December 26, 2025, to $19.72 on December 29, 2025, representing a decline of over 42% in a single day [3]. Group 3: Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company based in Novato, California, focusing on treatments for rare diseases [2].

Core View - Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements regarding the efficacy of its drug setrusumab for Osteogenesis Imperfecta [1][1][1] Class Action Details - The class period for the lawsuit is from August 3, 2023, to December 26, 2025, and investors have until April 6, 2025, to seek appointment as lead plaintiff [1][1] - The lawsuit alleges that Ultragenyx misrepresented the reliability of data from its Phase III Orbit study, which failed to show a statistically significant reduction in annualized fracture rate [1][1] - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance, leading to a stock price drop of over 25% [1][1] - Further, on December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies did not meet primary endpoints, resulting in a stock price decline of more than 42% [1][1] Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ultragenyx common stock during the class period to seek lead plaintiff status, representing the interests of all class members [1][1] - The lead plaintiff can choose a law firm to litigate the case, and participation in any potential recovery does not depend on being the lead plaintiff [1][1] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1][1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [1][1]

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the efficacy of its drug setrusumab, impacting investors who purchased stock between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false statements about setrusumab's ability to increase bone density and its correlation with reduced fracture rates, which were misrepresented to investors [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having secured significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking highly in the industry since 2013 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about the efficacy of its drug setrusumab in treating Osteogenesis Imperfecta [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Ultragenyx to contact them directly to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Ultragenyx [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives made false and misleading statements regarding the effects of setrusumab, creating a false impression of reliable information while downplaying risks associated with the Phase III Orbit study [4]. - Ultragenyx's optimism regarding the Phase III Orbit study's results was deemed misplaced, as the company failed to adequately disclose risks related to the study's design and results [4]. Group 3: Stock Performance Impact - On July 9, 2025, Ultragenyx announced that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [5]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [6][7].

SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025. Ultragenyx is a biopharmaceutical company focused on rare and ultrarare genetic disorders. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Invest ...

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly making false and misleading statements regarding its drug candidate's performance during a Phase III trial [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from August 3, 2023, to December 26, 2025, with a deadline for lead plaintiff appointments set for April 6, 2026 [2]. - The complaint alleges that Ultragenyx created falsely optimistic beliefs about its drug candidate's performance, failing to achieve statistically significant endpoints despite positive communications [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the efficacy of setrusumab, impacting investors who purchased stock between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false or misleading statements about setrusumab's potential, specifically that while it increases bone density, it does not correlate with a decrease in fracture rates, contrary to management's claims [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking highly in the industry since 2013 [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the efficacy of setrusumab, impacting investors who purchased stock between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false statements about setrusumab's potential, specifically that while it increases bone density, this does not correlate with a decrease in fracture rates, contrary to management's claims [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].